A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
← catalyst calendarNCT06978244 · readout ≤ 102 d
Sponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
24actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-29 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ocular Pain
Interventions
- Drug: BL1332 ophthalmic solution
- Drug: BL1332 ophthalmic vehicle
Primary outcomes
what the primary-completion date above is the date OFIncidence of DLTs (dose-limiting toxicities)
measured Approximately 6 months
Incidence of treatment-emergent AEs (TEAEs)
measured Approximately 6 months
Treatment-emergent changes in systemic and ocular safety assessments
measured Approximately 6 months
PK profiles and following parameter, where data allow (Cmax)
measured Approximately 6 months
PK profiles and following parameter, where data allow ( Tmax)
measured Approximately 6 months
PK profiles and following parameter, where data allow (Ctau)
measured Approximately 6 months
PK profiles and following parameter, where data allow (Tlast)
measured Approximately 6 months
PK profiles and following parameter, where data allow ( AUClast)
measured Approximately 6 months
PK profiles and following parameter, where data allow (AUCtau)
measured Approximately 6 months
PK profiles and following parameter, where data allow (AUCinf)
measured Approximately 6 months
PK profiles and following parameter, where data allow (ke1)
measured Approximately 6 months
PK profiles and following parameter, where data allow (t1/2)
measured Approximately 6 months
Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed